Company / Free Cash Flow
PALVELLA THERAPEUTICS, INC. Free Cash Flow History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$13.9M
FY2023
5-year range
-$61.0M / -$13.9M
FY2019-FY2023
Trend
+77.2%
vs FY2022
Sector context
#71 of 194
Health Care
What the data says
At -$14M, PALVELLA THERAPEUTICS, INC.'s free cash flow ranks #71 of 194 in the Health Care sector. Free Cash Flow has fluctuated over the past 9 years, ranging from -$61M in FY2022 to $48M in FY2018.
Based on SEC 10-K filings.
-$14M in FY2023.
Improved from -$49M to -$14M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#71 of 194 in Health CareTop 37% of 194This company -$13.9M Sector average $470.8M
▼
-102.9% below sector average
Key checks
Key Insights
- In FY2023, free cash flow increased 77.2% year-over-year.
- Ranks #71 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2018.
- Lowest free cash flow in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 1.15 (distress zone, below 1.8 threshold)
- Strong profit margin: 43.7%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -$13.9M | +77.2% |
| FY2022 | -$61.0M | -25.4% |
| FY2021 | -$48.6M | +11.5% |
| FY2020 | -$54.9M | +0.0% |
| FY2019 | -$54.9M | -214.9% |
| FY2018 | $47.8M | +419.8% |
| FY2017 | -$14.9M | +0.0% |
| FY2016 | -$14.9M | -12.2% |
| FY2015 | -$13.3M | -4613.2% |
As of FY2023 · SEC 10-K Annual Filings · Updated Jun 30, 2026